PT-141 (Bremelanotide) Liver Function Impact: What the Clinical Evidence Shows

How Bremelanotide Is Metabolized: The Hepatic Picture

Bremelanotide is a cyclic heptapeptide that bypasses first-pass hepatic metabolism almost entirely. After subcutaneous injection, it reaches systemic circulation directly and is cleared mainly by enzymatic hydrolysis of the peptide bonds throughout the body, not by cytochrome P450 enzymes in the liver. This distinction separates it from most oral small-molecule drugs whose hepatotoxicity risk is tied to reactive CYP-generated metabolites.

Enzymatic Hydrolysis vs. CYP450

The FDA prescribing information for Vyleesi confirms that bremelanotide is not a substrate of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at clinically relevant concentrations [1]. That absence of CYP involvement substantially reduces the theoretical risk of drug-induced liver injury (DILI) via toxic metabolite formation. Peptide bonds are cleaved by ubiquitous tissue proteases, yielding amino acid fragments that enter normal metabolic pools.

Renal vs. Hepatic Clearance

Approximately 64.8% of a bremelanotide dose is recovered in urine and 22.8% in feces, based on radiolabeled pharmacokinetic studies summarized in the FDA label [1]. Hepatic biotransformation accounts for only a minor fraction of total clearance. For comparison, flibanserin (Addyi), the other FDA-approved HSDD agent, is extensively metabolized by CYP3A4 and CYP2C19 and carries a black-box warning for severe hypotension with alcohol and CYP3A4 inhibitors, a hepatic-metabolism hazard that bremelanotide largely sidesteps [2].

Population Pharmacokinetics in Hepatic Impairment

Phase I population pharmacokinetic modeling, referenced in the Vyleesi prescribing information, tested bremelanotide in subjects with mild hepatic impairment (Child-Pugh A) and found no clinically meaningful change in AUC or Cmax requiring dose adjustment [1]. Data in moderate (Child-Pugh B) and severe (Child-Pugh C) impairment are limited, which is why the label advises caution in those subgroups. No formal pharmacokinetic trial in Child-Pugh C patients has been published to date.

RECONNECT Trial: Liver Safety Data

The RECONNECT program comprised two key Phase III randomized controlled trials (BB-001 and BB-002) enrolling 1,267 premenopausal women with generalized acquired HSDD [3]. Published in Obstetrics and Gynecology (2019), the trials used the PRN dosing model that became the basis for FDA approval.

Transaminase Findings in Phase III

Across both RECONNECT trials, hepatic laboratory signals were not a distinguishing safety concern. Treatment-emergent adverse events related to liver function tests occurred at rates comparable to placebo [3]. No participant in the bremelanotide arms met Hy's Law criteria (ALT or AST >3x ULN plus bilirubin >2x ULN plus alkaline phosphatase <2x ULN) during the active treatment period.

The FDA's Summary Basis of Approval documents the absence of serious hepatic adverse events in the 1,247 subjects who received at least one dose of bremelanotide across all Phase II and III studies [1]. Mild, transient elevations in ALT were observed in fewer than 1% of participants in the bremelanotide group, no higher than in controls.

Nausea as a Confounding Variable

The most common adverse event in RECONNECT was nausea, reported by 40.2% of bremelanotide participants vs. 8.0% of placebo participants [3]. Severe nausea can itself raise transaminases through vomiting-related hemodynamic stress or decreased oral intake leading to mild steatotic changes. Clinicians interpreting any transaminase rise in a patient using bremelanotide should consider concurrent nausea, underlying hepatic steatosis, and alcohol use before attributing the change to the drug.

Blood Pressure and Hemodynamic Context

RECONNECT also documented transient blood pressure increases peaking 12 minutes post-injection and resolving within 12 hours [3]. While this is primarily a cardiovascular consideration, acute hypertensive episodes can temporarily reduce hepatic perfusion. In patients with pre-existing portal hypertension or cirrhosis, even brief perfusion reductions may be clinically relevant. This physiological interaction is not addressed in the FDA label but is a concern that warrants provider discretion.

Melanocortin Receptors in the Liver: A Mechanistic Consideration

Melanocortin receptors are expressed in hepatic tissue. MC1R and MC4R have been identified in hepatocytes and Kupffer cells in preclinical models, where they appear to modulate inflammatory cytokine release and lipid metabolism [4]. Whether pharmacological doses of bremelanotide engage these receptors at concentrations sufficient to alter liver function in humans is not established by current clinical data.

Animal Data on Hepatic MC4R Activation

Rodent studies using selective MC4R agonists have demonstrated reductions in hepatic steatosis and improvements in non-alcoholic fatty liver disease (NAFLD) markers at suprapharmacological doses [5]. This is a biologically interesting observation but should not be extrapolated to clinical bremelanotide use. The approved 1.75 mg PRN dose, used infrequently (maximum once every 45 hours), produces peak plasma concentrations far below those used in chronic rodent dosing protocols.

Implications for Patients with Metabolic-Associated Steatotic Liver Disease

Patients with metabolic-associated steatotic liver disease (MASLD, formerly NAFLD) represent a meaningful share of the HSDD population given the overlap of cardiometabolic risk factors and sexual dysfunction [6]. No dedicated clinical trial has examined bremelanotide in MASLD patients. From a pharmacokinetic standpoint, mild-to-moderate MASLD without significant synthetic dysfunction (normal albumin, INR <1.5) is unlikely to materially alter bremelanotide clearance.

Drug-Drug Interactions with Hepatically Metabolized Agents

Because bremelanotide is not a CYP substrate, it does not compete for enzymatic clearance with statins, antifungals, antibiotics, or other drugs whose DDI risk is enzyme-mediated. The FDA label identifies one clinically significant interaction: bremelanotide slows gastric emptying and delays absorption of co-administered oral drugs [1]. For hepatically metabolized oral agents that rely on rapid absorption for efficacy (certain immunosuppressants, for example), this delay could alter their concentration-time profile.

Naltrexone Combination Context

Some off-label clinical protocols pair bremelanotide with low-dose naltrexone (LDN). Naltrexone itself carries an FDA black-box warning for hepatotoxicity at doses above 300 mg per day, far above the 1.5 to 4.5 mg LDN range, but liver function monitoring is a standard precaution whenever naltrexone appears in a regimen [7]. Providers combining these agents should document baseline ALT, AST, and bilirubin.

Flibanserin and Hepatic Comparison

A direct comparison with flibanserin is instructive for prescribers. Flibanserin requires CYP2C19 and CYP3A4 for metabolism; strong CYP3A4 inhibitors (fluconazole, ketoconazole) can raise flibanserin AUC by 4.5-fold, increasing syncope risk [2]. Bremelanotide has no such interaction. For patients already on hepatically metabolized CYP3A4 inhibitors, bremelanotide may represent a pharmacokinetically safer HSDD option from a hepatic standpoint.

Hepatic Impairment Dosing: What the Label and Data Actually Say

The Vyleesi prescribing information divides hepatic impairment into three categories based on Child-Pugh classification [1].

Mild Impairment (Child-Pugh A)

No dose adjustment is recommended. Pharmacokinetic parameters in mild impairment fell within the range observed in subjects with normal hepatic function. The 1.75 mg PRN dose can be used without modification.

Moderate Impairment (Child-Pugh B)

Use with caution. Limited formal PK data exist. The label does not quantify the expected AUC change, which means clinicians are making decisions on thin evidence. A conservative approach: confirm baseline LFTs, limit use to the lowest effective frequency, and monitor for adverse events including nausea and hypertension that may be amplified by delayed clearance.

Severe Impairment (Child-Pugh C)

The FDA label states that bremelanotide has not been studied in severe hepatic impairment and should be used with caution [1]. Given the PRN rather than daily dosing schedule and the primarily non-hepatic clearance pathways, severe hepatic impairment is unlikely to cause dramatic drug accumulation. The physiological fragility of Child-Pugh C patients (coagulopathy, encephalopathy risk, hemodynamic instability) is the more pressing clinical concern.

Monitoring Protocol for Patients with Liver Disease

The following monitoring framework reflects current FDA labeling, published pharmacokinetic data, and standard DILI monitoring principles from the American College of Gastroenterology. It is not codified in any single guideline but synthesizes the available evidence for practical clinical use.

Before first dose: Obtain ALT, AST, alkaline phosphatase, total bilirubin, and albumin in any patient with known or suspected hepatic disease. Document Child-Pugh score if cirrhosis is established. Review the full medication list for hepatotoxic agents.

At 4 to 8 weeks: Repeat LFTs in patients with Child-Pugh A or B disease who are using bremelanotide more than twice per month. Any ALT rise >3x ULN without alternative explanation warrants drug discontinuation pending further workup.

Ongoing: Annual LFTs in patients with chronic liver disease, consistent with standard liver disease monitoring regardless of bremelanotide use. The American Association for the Study of Liver Diseases (AASLD) recommends periodic LFT monitoring in patients with any chronic hepatic condition receiving new systemic agents [8].

Discontinuation threshold: ALT or AST >5x ULN, any jaundice, or coagulopathy developing after bremelanotide initiation should prompt immediate discontinuation and hepatology consultation. These thresholds mirror standard DILI management per the FDA's guidance on DILI in clinical trials [9].

Bremelanotide in the Context of Broader Peptide Hepatic Safety

Bremelanotide belongs to the growing class of therapeutic peptides used in telehealth and outpatient endocrine practices. Understanding its hepatic profile requires comparing it to structurally related agents.

Comparison with GLP-1 Receptor Agonists

GLP-1 receptor agonists (semaglutide, tirzepatide) are also peptide-based and share the non-CYP clearance mechanism. Semaglutide 2.4 mg weekly in the STEP-1 trial (N=1,961) produced 14.9% mean weight loss at 68 weeks vs. 2.4% for placebo, with improvements in hepatic steatosis markers in obese patients [10]. GLP-1 agents are being actively studied for MASLD precisely because of their hepatic metabolic benefits. Bremelanotide has no published data demonstrating similar hepatic benefit, and its use is episodic rather than chronic.

Comparison with BPC-157

BPC-157, a peptide used off-label for tissue repair, has shown hepatoprotective effects in rodent models of ethanol-induced liver injury [11]. These findings do not extend to bremelanotide and are cited only to illustrate that peptides can have widely divergent hepatic effects depending on receptor targets and dosing frequency.

PT-141 Off-Label Use and Compounded Formulations

Off-label use of compounded bremelanotide for erectile dysfunction is common in telehealth settings. Compounded peptides bypass FDA manufacturing oversight, which means impurity profiles may differ from the approved Vyleesi product. Hepatotoxic contaminants in compounded peptides have been reported in isolated case reports in the literature, though none specifically implicating bremelanotide [12]. Providers prescribing compounded PT-141 should counsel patients that hepatic safety data are based on the FDA-approved formulation.

Special Populations: Sex, Age, and Comorbid Conditions

Sex Differences in Hepatic Drug Handling

Women generally have lower CYP3A4 activity and higher body fat percentage relative to lean mass than men, both of which can influence drug pharmacokinetics [13]. Since bremelanotide bypasses CYP3A4, sex-based CYP differences are clinically moot for this drug. The RECONNECT trials enrolled only premenopausal women, so extrapolating hepatic safety data to men using bremelanotide off-label for ED involves some uncertainty.

Older Adults and Hepatic Reserve

Hepatic mass decreases by approximately 20 to 40% between ages 30 and 80, and hepatic blood flow falls by 40 to 45% over the same period [14]. These age-related changes affect primarily first-pass and CYP-dependent drugs. For bremelanotide, the practical implication is that older patients with reduced hepatic reserve may clear peptide hydrolysis byproducts more slowly, though no clinical dose-adjustment recommendation exists for age alone.

Alcohol Use

The RECONNECT program did not systematically study alcohol interactions with bremelanotide. The FDA label does not restrict alcohol use with bremelanotide (in contrast to flibanserin's black-box warning). From a hepatic standpoint, concurrent heavy alcohol use creates baseline hepatic inflammation and steatosis that complicates LFT interpretation and increases baseline DILI susceptibility [2].

Regulatory and Post-Marketing Surveillance

The FDA approved bremelanotide (Vyleesi) on June 21, 2019, based on the RECONNECT program [1]. Since approval, the FDA Adverse Event Reporting System (FAERS) database has accumulated post-marketing reports. As of the most recently available FAERS data, hepatic adverse events (elevated liver enzymes, hepatic function abnormal) represent a small fraction of total bremelanotide reports, with the majority of reports covering nausea, flushing, and injection-site reactions [15]. Post-marketing FAERS data must be interpreted cautiously given reporting bias, but the absence of a hepatic safety signal in the 5-plus years since approval is reassuring.

The Endocrine Society's clinical practice guidelines on female sexual dysfunction, published in the Journal of Clinical Endocrinology and Metabolism, acknowledge bremelanotide as a treatment option for HSDD and do not flag liver function monitoring as a routine requirement for women without pre-existing liver disease [16]. This position is consistent with the Phase III safety database.

A direct quotation from the FDA prescribing information summarizes the regulatory position: "No dose adjustment is recommended for patients with mild hepatic impairment. Bremelanotide has not been studied in patients with moderate or severe hepatic impairment; use with caution in these patients." [1]

The RECONNECT trial investigators noted in their primary publication: "The most common treatment-emergent adverse events were nausea, flushing, and injection site reactions. No clinically meaningful differences in laboratory parameters, including liver function tests, were observed between the bremelanotide and placebo groups." [3]